Results: Short term UDCA administration stimulated BA synthesis by reducing circulating fibroblast growth factor 19 and farnesoid X receptor (FXR) activation, resulting in cholesterol 7α-hydroxylase induction mirrored by elevated C4 and 7α-hydroxycholesterol. Enhanced BA formation depleted hepatic and LDL-cholesterol with subsequent ...

2023年3月4日 · udca和lca都是fxr激动剂，可以通过fxr-fgf15途径减轻代谢综合征。 当用LCA和UDCA治疗时，肥胖小鼠的胆固醇、血浆甘油三酯和血浆脂肪酸水平降低，这是由于FXR-FGF15的激活。

Here we show that short term UDCA administration, by replacing hydrophobic FXR-agonistic BAs and thereby reducing FXR anti-lipogenic effects, impacts on lipid conversion processes via elevated hepatic SCD expression.

2023年10月9日 · 贾伟教授团队此前研究表明，回肠中猪胆酸类（HCAs）可以同时激活TGR5和抑制FXR，促进肠道GLP-1的合成和分泌，降低血糖【6】。 BAs在调节甘油三酯（TG）和胆固醇代谢中起关键作用。 它们以FXR小异二聚体伴侣 (SHP)依赖的方式，通过抑制脂肪酸和TG合成的主要调节因子来抑制脂肪生成。 FXR激活还通过调节载脂蛋白CII (ApoCII)、ApoCIII和极低密度脂蛋白 (VLDL)受体的表达，促进TG水解并帮助TG从血清中清除。 BAs还调节脂质代谢的其他关 …

2022年12月5日 · We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we reveal that...

2023年1月28日 · In the present study we have compared the effects of BAR502, a dual FXR/GPBAR1 ligand) alone or in combination with ursodeoxycholic acid (UDCA) in a model of NAFLD/NASH induced by feeding...

2023年7月26日 · 研究人员发现使用非处方植物类固醇z-guggulsterone（ZGG）和非专利药物熊去氧胆酸（UDCA）可以减少FXR信号传导并下调人肺，胆管细胞和肠道类器官以及小鼠和仓鼠相应组织中的ACE2受体蛋白的表达。

2 天之前 · FXR activation is involved in the hepatoprotective effect of SIT in vivo and in vitro. ... Although UDCA is authorized for the cure of cholestasis, about 40 % of individuals with PBC do not show improvement with UDCA (Haange et al., 2022). PBC patients unresponsive to UDCA therapy can next be treated with OCA.

5 天之前 · Obeticholic acid (OCA), a ligand for farnesoid-X-receptor (FXR), and ursodeoxycholic acid (UDCA), an agonist for G-protein coupled bile acid receptor 1 (GPBAR1), have been used to treat liver ...

2 天之前 · For those with an incomplete response to UDCA, about 20-30% of patients with PBC, obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, was officially approved in 2016, based on the result of successful phase 3 clinical trial [8]. Recently, peroxisome proliferator-activated receptor (PPAR) agonists have been attracting attention as an ...